.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SURMOUNT-1 evaluated once-weekly tirzepatide in adults with obesity or overweight and without diabetes. Across the studied doses, tirzepatide produced large reductions in body weight compared with placebo over 72 weeks, with a substantial proportion of participants achieving weight-loss thresholds of 15%, 20% or more. The study helped establish dual GIP/GLP-1 receptor agonism as a major new approach to obesity pharmacotherapy. For internists, the practical implication is that obesity treatment can now include highly effective incretin-based medicines, but selection should remain individualized. Dose escalation, gastrointestinal tolerability, treatment cost and long-term adherence affect real-world success. The trial also reinforces that pharmacotherapy works best as part of comprehensive obesity care rather than as a stand-alone intervention. Patients should be assessed for hypertension, sleep apnea, diabetes, fatty liver disease and cardiovascular risk, because meaningful weight loss may influence multiple comorbidities. The central clinical task is not simply prescribing a potent drug but building a sustainable chronic-disease plan around it.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SURMOUNT-1 evaluated once-weekly tirzepatide in adults with obesity or overweight and without diabetes. Across the studied doses, tirzepatide produced large reductions in body weight compared with placebo over 72 weeks, with a substantial proportion of participants achieving weight-loss thresholds of 15%, 20% or more. The study helped establish dual GIP/GLP-1 receptor agonism as a major new approach to obesity pharmacotherapy. For internists, the practical implication is that obesity treatment can now include highly effective incretin-based medicines, but selection should remain individualized. Dose escalation, gastrointestinal tolerability, treatment cost and long-term adherence affect real-world success. The trial also reinforces that pharmacotherapy works best as part of comprehensive obesity care rather than as a stand-alone intervention. Patients should be assessed for hypertension, sleep apnea, diabetes, fatty liver disease and cardiovascular risk, because meaningful weight loss may influence multiple comorbidities. The central clinical task is not simply prescribing a potent drug but building a sustainable chronic-disease plan around it.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
